We currently have projects within hemophilia / hematology, autoimmune diseases / inflammation and inherited metabolic disorders in our development pipeline.
|
|
|
|
|
|
|
|
|
Hemophilia A
|
rFVIIIFc |
BiogenIdec |
|
|
|
|
|
Hemophilia B
|
rFIXFc |
BiogenIdec |
|
|
|
|
| Prevention of growth restriction in premature infants |
Kiobrina® |
|
|
|
|
|
| New orphan indications, eg. CAPS |
Kineret® |
|
|
|
|
|
| Second-line treatment of Hepatitis C |
Multiferon® |
|
|
|
|
|
The expected newsflow from our development pipeline is shown in the table below.
|
|
|
| Kiobrina® (Growth restriction): PhIII, results |
2013
|
| rFIXFc (Hemophilia B): PhIII, results |
2011/2012
|
| rFVIIIFc (Hemophilia A): PhIII, results |
2012/2013
|